Literature DB >> 16036090

Postmenopausal osteoporosis.

Peter Selby1.   

Abstract

The postmenopausal state is the most common underlying cause for osteoporosis and most of our understanding of the condition relates to this group. Recent evidence has suggested that hormone therapy may no longer have the pre-eminent place it once held but the same studies have also confirmed its antifracture efficacy. However, an increasing variety of alternative therapies are available for the postmenopausal woman. Furthermore, recent understanding of the mechanisms of bone loss after estrogen withdrawal, suggest that newer even better targeted therapies might be developed in the future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16036090     DOI: 10.1007/s11914-004-0018-y

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  31 in total

1.  The effect of a single dose of osteoprotegerin in postmenopausal women.

Authors:  P J Bekker; D Holloway; A Nakanishi; M Arrighi; P T Leese; C R Dunstan
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

2.  Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.

Authors:  S R Cummings; L Palermo; W Browner; R Marcus; R Wallace; J Pearson; T Blackwell; S Eckert; D Black
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

3.  Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis).

Authors:  J Buehler; P Chappuis; J L Saffar; Y Tsouderos; A Vignery
Journal:  Bone       Date:  2001-08       Impact factor: 4.398

4.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

5.  Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

Authors:  J A Stakkestad; L I Benevolenskaya; J J Stepan; A Skag; A Nordby; E Oefjord; A Burdeska; I Jonkanski; P Mahoney
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

6.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

8.  Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.

Authors:  Cyrus Cooper; Ronald D Emkey; Robert H McDonald; Gillian Hawker; Gerolamo Bianchi; Katie Wilson; Ralph C Schimmer
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

9.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

10.  Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

Authors:  Eugene McCloskey; Peter Selby; Mike Davies; John Robinson; Roger M Francis; Judith Adams; Karthik Kayan; Monique Beneton; Tarja Jalava; Liisa Pylkkänen; Juha Kenraali; Sakari Aropuu; John A Kanis
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

View more
  5 in total

1.  Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis.

Authors:  Yang Sun; Yue Li; Jiangbi Li; Xiaoping Xie; Feng Gu; Zhenjiang Sui; Ke Zhang; Tiecheng Yu
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

2.  Management of age-related osteoporosis and prevention of associated fractures.

Authors:  Eric J Maclaughlin; Rebecca B Sleeper; Danny McNatty; Cynthia L Raehl
Journal:  Ther Clin Risk Manag       Date:  2006-09       Impact factor: 2.423

3.  Analysis and Validation of Hub Genes in Blood Monocytes of Postmenopausal Osteoporosis Patients.

Authors:  Yi-Xuan Deng; Wen-Ge He; Hai-Jun Cai; Jin-Hai Jiang; Yuan-Yuan Yang; Yan-Rong Dan; Hong-Hong Luo; Yu Du; Liang Chen; Bai-Cheng He
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-13       Impact factor: 5.555

4.  Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo.

Authors:  Bin Zhou; Kun Peng; Guoqiang Wang; Weihua Chen; Yijun Kang
Journal:  Calcif Tissue Int       Date:  2021-02-24       Impact factor: 4.333

5.  Mesenchymal progenitors in osteopenias of diverse pathologies: differential characteristics in the common shift from osteoblastogenesis to adipogenesis.

Authors:  Bingdong Sui; Chenghu Hu; Li Liao; Yichen Chen; Xinyi Zhang; Xin Fu; Chenxi Zheng; Meng Li; Ling Wu; Xinyi Zhao; Yan Jin
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.